MMED:CC News and Press, MIND MEDICINE INC. From 05/12/22

MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management Canada NewsWire - Webinar to feature presentations from Kelly E. Dunn , PhD, MBA, and Stuart Gitlow , MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT - ...

MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders Canada NewsWire - Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB),...

MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update Canada NewsWire NEW YORK , May 9, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical st...

Tesla CEO Elon Musk recently stated on Twitter that psychedelic substances and other plant-based drugs were effective as treatments for a number of mental health conditions. Musk has in the past smoked a joint during a livestream video. The tweet in question is an excerpt from a conversa...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin , the psychoactive substance found in magic mushrooms. Authorities plan to greenlight a par...

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial...

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium PR Newswire - "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety med...

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer PR Newswire - Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas includ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 –  Depression and anxiety affect millions around the world and the venom of a toad is the latest  psychedelic compound being used as an alternative treat...